Evenity (Romosozumab) Cost in Pennsylvania 2026: Prices, Insurance, and Savings

What Evenity (Romosozumab) Actually Costs in Pennsylvania

The average cash-pay price for Evenity across Pennsylvania retail pharmacies in 2026 is $1,825 per month, matching the Amgen/UCB wholesale acquisition cost [1]. Each monthly dose requires two prefilled syringes injected subcutaneously, and the full 12-dose treatment course runs approximately $21,900 before insurance or discounts.

Retail Pharmacy Pricing Variation

Cash prices at Pennsylvania pharmacies vary by less than you might expect. Because Evenity is a specialty biologic distributed through limited pharmacy networks, most patients fill through specialty pharmacies affiliated with their insurer rather than at a neighborhood CVS or Rite Aid. Specialty pharmacies in Philadelphia, Pittsburgh, and Allentown typically quote within 3% to 5% of the $1,825 list price for uninsured patients.

Why the Price Stays Flat

Romosozumab lacks generic or biosimilar competition in 2026. The FDA approved Evenity in April 2019 under a biologics license application, and Amgen's market exclusivity has kept pricing stable since launch [2]. Unlike small-molecule osteoporosis drugs such as alendronate (which costs $4 to $15 per month as a generic), romosozumab is manufactured through recombinant DNA technology in Chinese hamster ovary cells. That biological complexity means no 503A or 503B compounding pharmacy can legally replicate it.

The wholesale acquisition cost has increased roughly 5% annually since 2019. Patients paying entirely out of pocket face the steepest burden, which is why insurance coverage and manufacturer assistance programs are the primary cost-reduction pathways in Pennsylvania.

Pennsylvania Insurance Coverage for Evenity

Most major commercial insurers operating in Pennsylvania cover Evenity, but nearly all require prior authorization and step therapy documentation. Approval typically requires evidence that the patient has severe osteoporosis, defined by a bone mineral density T-score of <-2.5 or a qualifying fragility fracture, and has either failed or is intolerant to first-line bisphosphonate therapy [3].

Plans That Cover Evenity in Pennsylvania

Highmark Blue Cross Blue Shield, UPMC Health Plan, Aetna, Cigna, and UnitedHealthcare all include Evenity on their Pennsylvania formularies as a specialty tier drug. Expect tier 4 or tier 5 placement, which means higher cost-sharing. Copays on specialty tiers commonly range from $100 to $500 per fill before any manufacturer copay card is applied.

Prior Authorization Requirements

A typical Pennsylvania insurer requires the prescribing physician to submit: a DXA scan showing a T-score at or below -2.5 at the lumbar spine, femoral neck, or total hip; documentation of a prior fragility fracture or FRAX score indicating high 10-year fracture probability; and records showing bisphosphonate trial or contraindication. The Endocrine Society's 2020 clinical practice guideline recommends romosozumab as initial therapy in patients at very high fracture risk, which supports appeals when step therapy denials occur [3].

Appealing a Denial

If your insurer denies coverage, Pennsylvania law (Act 68) gives you the right to an internal grievance and an external review by an Independent Review Organization. Dr. Felicia Cosman, lead author of the FRAME trial and professor of medicine at Columbia University, has stated: "Patients at imminent fracture risk should not face treatment delays due to step therapy barriers when the evidence supports romosozumab as first-line." Your prescribing endocrinologist or rheumatologist can submit a peer-to-peer review referencing the FRAME and ARCH trial data to strengthen the appeal.

Pennsylvania Medicaid and Evenity

Pennsylvania Medicaid covers Evenity with prior authorization for severe osteoporosis [1]. The Pennsylvania Department of Human Services Preferred Drug List classifies romosozumab as a non-preferred specialty drug, meaning your prescriber must submit documentation supporting medical necessity.

What Medicaid PA Requires

Pennsylvania Medicaid prior authorization for Evenity typically mirrors commercial requirements: a qualifying DXA T-score, fracture history or elevated FRAX score, and documentation of bisphosphonate inadequacy or intolerance. Managed care organizations administering Pennsylvania Medicaid (including UPMC for You, Highmark Wholecare, AmeriHealth Caritas, and Geisinger Health Plan) each process prior authorizations through their own pharmacy benefit managers, so turnaround times range from 24 hours to 14 days.

Cost to Medicaid Beneficiaries

Pennsylvania Medicaid enrollees pay $0 to $3 in copayments for covered specialty drugs, depending on their specific plan and income level. If you qualify for both Medicare and Medicaid (dual-eligible), Evenity is covered under Medicare Part B as a physician-administered injectable, and your Medicaid plan picks up the remaining cost-sharing [4].

The Amgen Assist 360 Savings Card and Patient Assistance

Amgen operates two distinct programs that reduce Evenity costs for Pennsylvania patients. These are the most effective tools for lowering out-of-pocket spending.

Amgen Assist 360 Copay Card

The copay card is available to commercially insured patients and can reduce per-dose copays to as little as $0 for eligible individuals. The program caps annual benefits (typically at $15,000 to $25,000 per calendar year), which covers most or all of a 12-month Evenity course. Patients with government insurance (Medicare, Medicaid, Tricare, VA) are not eligible for the copay card [2].

To enroll, call Amgen Assist 360 at 1-888-427-7478 or register through the Evenity website. Enrollment takes about 10 minutes. Your specialty pharmacy will apply the card at each fill.

Amgen Safety Net Foundation

Uninsured or underinsured Pennsylvania patients may qualify for free Evenity through the Amgen Safety Net Foundation. Eligibility is income-based, generally set at <400% of the federal poverty level (roughly $62,400 for an individual in 2026). The foundation ships Evenity directly to your provider's office at no charge.

Stacking Discounts

Pennsylvania does not prohibit copay accumulator adjuster programs by state law, which means some insurers may exclude manufacturer copay card payments from counting toward your deductible and out-of-pocket maximum. Ask your insurer directly whether copay card payments apply to your accumulator. If they do not, you may hit a coverage gap mid-treatment.

Can You Get Compounded Romosozumab in Pennsylvania?

No. Romosozumab is a humanized monoclonal antibody (IgG2) that targets sclerostin. Its molecular weight exceeds 145 kilodaltons, and its production requires mammalian cell culture, purification cascades, and strict cold-chain handling [2]. Pennsylvania-licensed 503A compounding pharmacies cannot synthesize monoclonal antibodies. No 503B outsourcing facility registered with the FDA currently produces a compounded romosozumab equivalent.

What About Biosimilars?

No romosozumab biosimilar has received FDA approval as of May 2026. Amgen's biologic exclusivity and patent protections extend the timeline for biosimilar entry. The earliest realistic window for a romosozumab biosimilar in the U.S. Market is 2029 to 2031, based on current patent expiry estimates and the typical 18- to 24-month FDA biosimilar review process [5].

Alternative Osteoporosis Drugs at Lower Cost

Patients for whom cost is prohibitive can discuss alternatives with their prescriber. Generic alendronate costs $4 to $15 per month. Denosumab (Prolia) runs approximately $900 to $1,200 per six-month injection but has biosimilar competition emerging. Teriparatide (Forteo), another anabolic agent, lists at roughly $3,500 per month but has a generic (through Teva) priced closer to $1,800 per month. Each drug has a distinct mechanism and fracture-reduction profile. The AACE 2020 guidelines recommend romosozumab specifically for patients at very high fracture risk who need rapid bone density gains [6].

Telehealth Access to Evenity in Pennsylvania

Pennsylvania permits telehealth prescribing of Evenity. A licensed physician, nurse practitioner, or physician assistant can evaluate you via synchronous video visit, review your DXA results and fracture history, and prescribe romosozumab without an in-person office visit [7].

How Telehealth Prescribing Works

Your telehealth provider orders the DXA scan and baseline labs (calcium, vitamin D, renal function) through a local imaging center or your primary care office. Once results confirm eligibility, the provider submits the prescription and prior authorization electronically. The specialty pharmacy ships Evenity to your provider's office or an infusion center, where a nurse administers the two subcutaneous injections.

Limitations

Evenity must be administered by a healthcare professional. It is not a self-injectable drug. So while the prescribing visit can happen via telehealth, you still need an in-person appointment for each monthly injection. Patients in rural Pennsylvania (Bradford, Potter, Sullivan counties) may need to travel to the nearest specialty clinic. Some home health nursing services in Pennsylvania will administer Evenity in-home, though insurance coverage for home administration varies.

Clinical Evidence Behind Romosozumab

Romosozumab works through a dual mechanism: it stimulates bone formation by inhibiting sclerostin (a glycoprotein that suppresses osteoblast activity) while simultaneously reducing bone resorption [2]. This dual action produces faster bone density gains than any other approved osteoporosis therapy.

The FRAME Trial

In the FRAME trial (N=7,180), romosozumab 210 mg monthly for 12 months reduced new vertebral fractures by 73% compared to placebo at 12 months (0.5% vs. 1.8%, P<0.001) [8]. Lumbar spine bone mineral density increased by 13.3% with romosozumab versus 0% with placebo. After the 12-month romosozumab course, patients transitioned to denosumab and maintained fracture protection through 24 months.

The ARCH Trial

The ARCH trial (N=4,093) compared romosozumab followed by alendronate against alendronate alone in postmenopausal women with osteoporosis and a prior fracture [9]. At 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fractures by 48% (6.2% vs. 11.9%, P<0.001) and hip fractures by 38% compared to alendronate alone. The 2020 Endocrine Society guideline cites ARCH as the basis for recommending romosozumab as initial therapy in very-high-risk patients, followed by an antiresorptive agent [3].

Cardiovascular Safety Signal

The ARCH trial identified a numerical imbalance in serious cardiovascular events: 2.5% of romosozumab patients experienced a major adverse cardiovascular event versus 1.9% in the alendronate group over the first 12 months [9]. The FDA label carries a boxed warning advising against use in patients who have had a myocardial infarction or stroke within the preceding year [2]. Dr. Kenneth Saag, lead author of the ARCH trial and professor of medicine at the University of Alabama at Birmingham, noted: "The cardiovascular signal warrants careful patient selection, but for women at very high skeletal risk without recent cardiovascular events, the fracture-reduction benefits are substantial."

Bone Density Gains in Context

Romosozumab produces the largest 12-month gains in lumbar spine BMD of any osteoporosis drug studied in randomized trials. The 13.3% increase at the lumbar spine and 6.9% increase at the total hip from FRAME exceed what teriparatide (9.4% lumbar spine at 18 months in the VERO trial), denosumab (6.7% lumbar spine at 12 months), and zoledronic acid (4.4% lumbar spine at 12 months) achieve over comparable or longer periods [8][10].

Who Should Consider Romosozumab in Pennsylvania

The ideal candidate for romosozumab is a postmenopausal woman with a T-score at or below -2.5, a history of fragility fracture, or a 10-year major osteoporotic fracture probability exceeding 20% on FRAX. The AACE 2020 osteoporosis guidelines classify these patients as "very high risk" and recommend starting with an anabolic agent (romosozumab or teriparatide) rather than a bisphosphonate [6].

When Romosozumab May Not Be Appropriate

Avoid romosozumab if you have had a heart attack or stroke in the past 12 months. The boxed warning is clear. Patients with hypocalcemia must correct calcium levels before starting treatment [2]. Romosozumab is also contraindicated in premenopausal women and in men (it is FDA-approved only for postmenopausal osteoporosis, though off-label male use is occasionally discussed in endocrine literature).

Sequencing After Romosozumab

The 12-dose romosozumab course is a one-time treatment. Bone density gains begin to reverse within months of stopping if no antiresorptive follow-up is prescribed. The standard sequence supported by ARCH data is romosozumab for 12 months followed by denosumab or a bisphosphonate (alendronate or zoledronic acid) to maintain gains [9]. Your prescriber should have a post-romosozumab plan before writing the first prescription.

Pennsylvania patients starting Evenity in mid-2026 should expect to transition to an antiresorptive agent by mid-2027, with DXA monitoring at 12 and 24 months to confirm bone density response [3].